New daily tablet doubles life expectancy for pancreatic cancer patients

A new drug called daraxonrasib has proven to be a breakthrough in pancreatic cancer treatment, doubling patients' life expectancy. Pancreatic cancer is considered the deadliest of all major cancer types. The drug is administered as a daily tablet.

Scientists have announced a significant breakthrough in pancreatic cancer treatment: a daily tablet called daraxonrasib has demonstrated the ability to double patients' life expectancy. Pancreatic cancer is considered the deadliest of all major cancer types, which is why the new drug has drawn considerable attention in the medical world.

Daraxonrasib is a tablet-based medication, which sets it apart from many other cancer drugs that must be administered intravenously in a hospital setting. Daily oral administration significantly simplifies treatment and improves patients' quality of life during the course of therapy.

The prognosis for pancreatic cancer has historically been very poor—most patients do not live more than a year following diagnosis. A doubling of life expectancy therefore represents a major advance, which could change treatment standards for this disease worldwide, including in Europe and Estonia.

According to medical experts, this represents one of the most important breakthroughs in pancreatic cancer treatment in recent decades. The drug developers hope that further research will confirm the results and that the medication will soon reach a wider patient population.